Issue 55

Inside the UK’s campaign to reschedule psilocybin with MP Crispin Blunt

UK Member of Parliament Crispin Blunt has championed the campaign to reschedule psilocybin for scientific and research purposes. Last month the honourable Mr Blunt raised the issue directly with Boris Johnson at Prime Minister’s Questions, with Johnson declaring he would get back to Blunt at the earliest opportunity.

This elevated the campaign to national headlines, and a week later COMPASS Pathways released data from its pivotal Phase IIb trial, which demonstrated psilocybin’s efficacy in treatment-resistant depression.

PSYCH sat down with Blunt and Timmy Davis, Psilocybin Rescheduling Project Manager at the Conservative Drug Policy Reform Group, to discuss the groundbreaking study and the future of the nation’s psychedelic healthcare industry.

Read More

AWAKN SIGNS MOU WITH NHS TO INCREASE ACCESSIBILITY OF PSYCHEDELICS

The partnership establishes a framework to assess the readiness for ketamine-assisted psychotherapy within the NHS.

Read More

DEA ONCE AGAIN BOOSTS PSILOCYBIN, MDMA AND DMT PRODUCTION QUOTAS

The federal agency now wants 3.2kg of MDMA produced in 2022 and 6kg of psilocybin made by the end of the year.

Read More

BUSINESS AND INVESTMENT

Q3 2021 financial results provided by atai Life Sciences, Cybin, Field Trip, Filament Health, MindMed, Mydecine and Silo Pharma.

Johnson & Johnson to split into two companies.

Clinics in the UK prescribing ketamine for depression.

Lobe Sciences to trade under LOBEF in the US.

Beatrice Society acquires MindSetting.

Novamind signs LOI to acquire Arizona clinics.

Vaxil pulls out of Short Wave acquisition.

MindBio Therapeutics gives update from LSD clinical trial.

MindMed starts recruitment for low-dose LSD trial.

Entheon Biomedical starts recruitment for ketamine clinical trial.

RYAH and Ei.Ventures enter LOI for drug delivery development.

CaaMTech partners with Wyoming University to study psychedelics.

Mycotopia Therapies to develop sublingual psilocybin tablet.

Way2Grow Biopharma obtains Dealer’s License from Health Canada.

Shanti Therapeutics files MDMA patent.

NanoAlchemie files drug delivery patent.

BetterLife Pharma provides update on LSD analogue.

PharmaTher provides update on psilocybin patch research.

Global Health Clinics partners with Cultivarium to develop psilocybin products.

SCIENCE AND RESEARCH

Blossom research briefing: psychedelics & depression.

New research brings psychedelic drugs a step closer to medical use.

Legalisation of psychedelic drugs would ‘broaden access to research’.

Ketamine and the brain: improved antidepressants.

Magic mushrooms show some success in battle against depression.

Psychedelic medicines associated with reduced daily opioid use.

The Psychedelics as Medicine Report: Third Edition was powered by Blossom, the psychedelic industry’s largest database of market intelligence.

Blossom supports the development of the sector by providing data on companies, their research and clinical trials, empowering operators and policymakers to make informed decisions.

Subscribe to the newsletter

REGULATION AND LEGISLATION

Warning of ‘wild west’ in depression treatment as UK clinics offer ketamine.

Australian doctor takes bid to treat patient with MDMA to court.

Veterans have become unlikely lobbyists in push to legalise psychedelic drugs.

Denver City Council could expand decriminalisation of psychedelics.

Psychedelic therapy research is on the horizon for Texas veterans with PTSD.

Bill aims to make Philadelphia a leader in psychedelic research.

Australian drug laws doing more harm than good.

Partner with us